438 related articles for article (PubMed ID: 34259140)
21. Abnormal Expression and Prognostic Significance of Bone Morphogenetic Proteins and Their Receptors in Lung Adenocarcinoma.
Xu Z; Chen C
Biomed Res Int; 2021; 2021():6663990. PubMed ID: 34036102
[TBL] [Abstract][Full Text] [Related]
22. A promising prognostic signature for lung adenocarcinoma (LUAD) patients basing on 6 hypoxia-related genes.
Luo J; Du X
Medicine (Baltimore); 2021 Dec; 100(50):e28237. PubMed ID: 34918689
[TBL] [Abstract][Full Text] [Related]
23. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
24. Construction and analysis of a novel ferroptosis-related gene signature predicting prognosis in lung adenocarcinoma.
Zhou J; Wang X; Li Z; Jiang R
FEBS Open Bio; 2021 Nov; 11(11):3005-3018. PubMed ID: 34499810
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma.
Zhang JT; Lin YC; Xiao BF; Yu BT
Med Sci Monit; 2019 Jun; 25():4264-4272. PubMed ID: 31175804
[TBL] [Abstract][Full Text] [Related]
26. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
28. An N
Chu X; Wang W; Sun Z; Bao F; Feng L
Math Biosci Eng; 2022 Jan; 19(1):253-270. PubMed ID: 34902990
[No Abstract] [Full Text] [Related]
29. Identification of a novel gene expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on TCGA and GEO databases.
Zhao J; Guo C; Ma Z; Liu H; Yang C; Li S
Lung Cancer; 2020 Nov; 149():90-96. PubMed ID: 33002836
[TBL] [Abstract][Full Text] [Related]
30. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
Chen J; Fu Y; Hu J; He J
Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
[TBL] [Abstract][Full Text] [Related]
32. A seven-gene prognostic model related to immune checkpoint PD-1 revealing overall survival in patients with lung adenocarcinoma.
Niu W; Jiang L
Math Biosci Eng; 2021 Jul; 18(5):6136-6154. PubMed ID: 34517527
[TBL] [Abstract][Full Text] [Related]
33. A Six-Gene Signature Predicts Survival of Adenocarcinoma Type of Non-Small-Cell Lung Cancer Patients: A Comprehensive Study Based on Integrated Analysis and Weighted Gene Coexpression Network.
Xie H; Xie C
Biomed Res Int; 2019; 2019():4250613. PubMed ID: 31886214
[No Abstract] [Full Text] [Related]
34. A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma.
Li X; Xu C; Min Y; Zhai Z; Zhu Y
Clin Respir J; 2023 Dec; 17(12):1349-1360. PubMed ID: 38071755
[TBL] [Abstract][Full Text] [Related]
35. Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
Chen J; Zhou R
PeerJ; 2021; 9():e10628. PubMed ID: 33520448
[TBL] [Abstract][Full Text] [Related]
36. A gene expression-based immune signature for lung adenocarcinoma prognosis.
Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
[TBL] [Abstract][Full Text] [Related]
37. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.
Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J
Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526
[TBL] [Abstract][Full Text] [Related]
38. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma.
Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C
Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818
[TBL] [Abstract][Full Text] [Related]
39. Identification of metabolism-related gene signature in lung adenocarcinoma.
Wang N; Wang H
Medicine (Baltimore); 2023 Nov; 102(47):e36267. PubMed ID: 38013279
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]